Clinical trials: Renal Transplant Rejection
Acute Transplant Rejection in Patients Receiving Allogeneic Renal Transplant
Generic Mycophenolate Mofetil Safety Study for Prophylaxis in de Novo Renal Transplant Patients in Jordan
The purpose of this observational study was to assess the safety and efficacy of generic mycophenolate mofetil in de novo renal transplant patients in Jordan where no visits or intervention(s) additional to the daily practice…
- Trial name
- MyOra-PASS (NCT03517982)
- Testing
- Mycophenolate Mofetil
- Where
- Jordan
- Volunteers
- 12 people
- Sponsor
- Hikma Pharmaceuticals LLC
Kidney Transplant Rejection
ddcfDNA in Kidney Transplant Recipients
The objective of this study is to predict subclinical Antibody-Mediated Rejection (ABMR) occurrences in de novo DSA-positive recipients maintaining stable renal function after transplantation.
- Trial name
- NCT06013358
- Testing
- AlloSeq cfDNA
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Seoul National University Hospital
Renal Transplant Rejection
Imaging Kidney Transplant Rejection Using Ferumoxytol-Enhanced Magnetic Resonance
The goal of this study is to develop a non-invasive imaging test for in vivo detection of kidney transplant rejection. The hypotheses are that 1) Ferumoxytol-MRI can generate accurate estimates of tissue iron concentrations and…
- Trial name
- NCT02006108
- Testing
- Feraheme, MRI-GE Healthcare 3 Tesla magnet
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Stanford University
Kidney Transplant Rejection
Antithymocyte Globulin and Azathioprine Versus Basiliximab and Mycophenolate Mofetil in Living Donor Kidney Transplantation
Kidney transplantation is the best available treatment option for patients with end stage renal disease. However, kidney transplantation requires life-long use of immunosuppressive medication.
- Trial name
- NCT03789006
- Testing
- Antithymocyte Immunoglobulin (Rabbit), Interleukin 2 Receptor Antagonist
- Where
- Sudan
- Volunteers
- 300 people
- Sponsor
- University of Khartoum
Renal Allograft Recipients
A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
The purpose of this study is to evaluate the benefits and risks of conversion of existing adolescent kidney allograft recipients aged 12 to less than 18 years of age to a belatacept-based immunosuppressive regimen as compared to…
- Trial name
- NCT04877288
- Testing
- Belatacept, Tacrolimus, Cyclosporine A
- Where
- 38 sites in United States, Argentina and 8 more
- Volunteers
- 102 people
- Sponsor
- Bristol-Myers Squibb
Kidney Transplant Rejection
Assessing AlloSure Dd-cfDNA Monitoring Insights of Renal Allografts With Longitudinal Surveillance
Prospective Observational Multicenter Cohort. External validation of donor derived cell free DNA in Renal Transplantation. Assessing performance of dd-cfDNA as a surveillance tool and its association with clinical outcomes.
- Trial name
- ADMIRAL (NCT04566055)
- Testing
- AlloSure
- Where
- 8 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- CareDx
Kidney Transplantation
Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplantation
In patients who receive an organ transplant, their body considers this organ as foreign and attempts to destroy it. This is called rejection.
- Trial name
- NCT00098735
- Testing
- FTY720
- Volunteers
- 140 people
- Sponsor
- Novartis Pharmaceuticals
Stage V Chronic Kidney Disease
Safety & Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipients Of A Kidney Transplant From A Deceased Donor
Primary Objective: To evaluate the safety and potential efficacy of eculizumab to prevent AMR in sensitized recipients of deceased donor kidney transplants.
- Trial name
- NCT01567085
- Testing
- Eculizumab
- Where
- 15 sites in Australia, France and 4 more
- Volunteers
- 80 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Kidney Transplantation
Prediction of Medication Compliance Following Renal Transplantation
The purpose of this study is to quantitate pre-transplant medication compliance, dialysis compliance, and related psychological variables, and then examine their validity as predictors of post-transplant noncompliant behaviors…
- Trial name
- NCT00148187
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Minnesota
Renal Transplant Rejection
Calcineurin Activity in Renal Recipients
The purpose is to define if calcineurin activity is a better biological parameter than blood concentration for the therapeutic tacrolimus monitoring.
- Trial name
- NCT01413685
- Testing
- Pharmacokinetics/dynamics
- Where
- France
- Volunteers
- 23 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Kidney Transplant Rejection, End Stage Renal Disease
Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients
The purpose of this study is to evaluate the safety and tolerability of TX200-TR101 and its effects on the donated kidney in living donor kidney transplant recipients.
- Trial name
- STEADFAST (NCT04817774)
- Testing
- TX200-TR101
- Where
- 5 sites in Belgium, Netherlands and 1 more
- Volunteers
- 26 people
- Sponsor
- Sangamo Therapeutics
Kidney Transplantation
Standard Induction With Basiliximab Versus No-Induction in Low Immunological Risk Kidney Transplant Recipients
Background: Induction therapy with IL-2 receptor antagonist (IL2-RA) is recommended as a first line agent in low immunological risk kidney transplant recipients.
- Trial name
- NCT04404127
- Testing
- Basiliximab 20 milligram [Simulect], Normal Saline
- Where
- Saudi Arabia
- Volunteers
- 140 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Kidney Transplant Rejection, Gastrointestinal Disorder, Functional
Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation
Patients who receive renal transplantation at Barnes Jewish Hospital (BJH) are placed on triple maintenance immunosuppression, which means that patients take 3 types of immunosuppression drugs to suppress their immune system…
- Trial name
- NCT02974686
- Testing
- Everolimus, Mycophenolic Acid
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Washington University School of Medicine
Rejection Chronic Renal, Kidney Transplant Rejection
Longitudinal Changes in Donor-Derived Cell-Free DNA With Tocilizumab Treatment for Chronic Antibody-Mediated Rejection
Our group recently reported that tocilizumab, a humanized monoclonal antibody against the IL-6 receptor, may be effective when administered monthly to patients with chronic antibody-mediated rejection (ABMR).
- Trial name
- NCT03859388
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Cedars-Sinai Medical Center
Viremia, Bacteremia
Treating Donors With Intravenous Immunoglobulin to Reduce Donor-Derived Infections
The goal of this clinical trial is to learn about the benefit of IVIG in donor-derived infections and the potential immunomodulatory effect on transplanted organs. The main questions it aims to answer are: 1.
- Conditions
- Viremia, Bacteremia, Acute Rejection of Renal Transplant
- Trial name
- NCT05799716
- Testing
- IVIG
- Volunteers
- 40 people
- Sponsor
- Shanghai Changzheng Hospital
Autoimmune Diseases
Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg Cells
The purpose of this pilot trial is to determine whether a conversion from calcineurin inhibitors (CNI) and mycophenolate mofetil (MMF) to a regimen consisting of efalizumab and sirolimus is associated with an increase in T…
- Trial name
- NCT00777400
- Testing
- Efalizumab
- Where
- United States
- Sponsor
- University of California, San Francisco
Kidney Transplantation
Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant
The efficacy and safety of FTY720 is being evaluated in patients who receive a kidney transplant.
- Trial name
- NCT00099736
- Testing
- FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids, FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids, MMF 2 g + full-dose Neoral (FDN) + corticosteroids
- Where
- 42 sites in United States
- Volunteers
- 696 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Transplant Failure and Rejection
Assessment of QSant™ for Underlying Allograft Rejection
The AQUA registry is a multi-center observational study to assess the clinical management of kidney transplant recipients (KTRs) with use of the QSant test.
- Trial name
- AQUA (NCT05282966)
- Testing
- QSant-TM Urine Test
- Volunteers
- 4,000 people
- Sponsor
- NephroSant
Kidney Transplant; Complications, Rejection of Renal Transplant
Urine CXCL10 Monitoring Trial in Kidney Transplant
This is a Phase II-III multi-center prospective randomized controlled clinical trial of incident adult renal transplant patients.
- Trial name
- NCT03206801
- Testing
- Kidney transplant biopsy
- Where
- 9 sites in Australia, Canada
- Volunteers
- 260 people
- Sponsor
- University of Manitoba
Graft Rejection
Randomized Trial for Mixed Acute Rejection
This study is being conducted to determine how safe and effective using an immune cell (b cell) depleting therapy and/or Thymoglobulin is in patients with a kidney transplant who are experiencing certain types of rejection.
- Trial name
- NCT00771875
- Testing
- Rabbit Antithymocyte Globulin (RATG), Rituximab, Bortezomib
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Cincinnati